Commonwealth Equity Services LLC Takes $5.92 Million Position in Aquestive Therapeutics, Inc. $AQST

Commonwealth Equity Services LLC acquired a new position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 1,058,725 shares of the company’s stock, valued at approximately $5,918,000. Commonwealth Equity Services LLC owned about 1.06% of Aquestive Therapeutics at the end of the most recent quarter.

Several other large investors have also modified their holdings of the company. Pale Fire Capital SE boosted its holdings in Aquestive Therapeutics by 25.5% during the second quarter. Pale Fire Capital SE now owns 1,676,451 shares of the company’s stock valued at $5,549,000 after acquiring an additional 340,767 shares during the period. Sio Capital Management LLC increased its stake in shares of Aquestive Therapeutics by 141.9% in the second quarter. Sio Capital Management LLC now owns 947,489 shares of the company’s stock worth $3,136,000 after purchasing an additional 555,860 shares during the period. Diametric Capital LP acquired a new position in shares of Aquestive Therapeutics during the 2nd quarter worth about $547,000. Everstar Asset Management LLC lifted its position in shares of Aquestive Therapeutics by 119.5% during the 2nd quarter. Everstar Asset Management LLC now owns 658,607 shares of the company’s stock worth $2,180,000 after purchasing an additional 358,607 shares during the last quarter. Finally, Daymark Wealth Partners LLC bought a new stake in Aquestive Therapeutics during the 2nd quarter valued at approximately $58,000. 32.45% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have commented on AQST shares. Piper Sandler lifted their price target on Aquestive Therapeutics from $5.00 to $8.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. JMP Securities boosted their target price on shares of Aquestive Therapeutics from $9.00 to $12.00 and gave the stock a “market outperform” rating in a research report on Thursday, October 9th. Citigroup reaffirmed an “outperform” rating on shares of Aquestive Therapeutics in a report on Thursday, October 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aquestive Therapeutics in a research report on Wednesday, October 8th. Finally, Wall Street Zen raised Aquestive Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $8.83.

Aquestive Therapeutics Stock Performance

Shares of NASDAQ:AQST opened at $3.52 on Thursday. Aquestive Therapeutics, Inc. has a 52 week low of $2.12 and a 52 week high of $7.55. The company’s fifty day moving average is $5.84 and its 200-day moving average is $5.25. The company has a market capitalization of $429.45 million, a PE ratio of -4.96 and a beta of 1.66.

Aquestive Therapeutics (NASDAQ:AQST) last announced its earnings results on Wednesday, November 5th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). The company had revenue of $12.81 million for the quarter, compared to analyst estimates of $12.94 million. On average, analysts forecast that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current year.

Aquestive Therapeutics Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.